Role of microRNA-520h in 20(R)-ginsenoside-Rg3-mediated angiosuppression |
Keung, Man-Hong
(Department of Biology, Faculty of Science, Hong Kong Baptist University)
Chan, Lai-Sheung (Department of Biology, Faculty of Science, Hong Kong Baptist University) Kwok, Hoi-Hin (Department of Biology, Faculty of Science, Hong Kong Baptist University) Wong, Ricky Ngok-Shun (Department of Biology, Faculty of Science, Hong Kong Baptist University) Yue, Patrick Ying-Kit (Department of Biology, Faculty of Science, Hong Kong Baptist University) |
1 | Kim VN, Nam JW. Genomics of microRNA. Trends Genet 2006;22:165-73. DOI |
2 | Ambros V. The functions of animal microRNAs. Nature 2004;431:350-5. DOI |
3 | Erson AE, Petty EM. MicroRNAs in development and disease. Clin Genet 2008;74:296-306. DOI |
4 | Chan LS, Yue PY, Mak NK, Wong RN. Role of microRNA-214 in ginsenoside- Rg1-induced angiogenesis. Eur J Pharm Sci 2009;38:370-7. DOI |
5 | Chan LS, Yue PY, Wong YY, Wong RN. MicroRNA-15b contributes to ginsenoside-Rg1-induced angiogenesis through increased expression of VEGFR-2. Biochem Pharmacol 2013;86:392-400. DOI |
6 | Chan YK, Kwok HH, Chan LS, Leung KS, Shi J, Mak NK, Wong RN, Yue PY. An indirubin derivative, E804, exhibits potent angiosuppressive activity. Biochem Pharmacol 2012;83:598-607. DOI |
7 | Nagpal M, Nagpal K, Nagpal PN. A comparative debate on the various antivascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin). Indian J Ophthalmol 2007;55:437-9. DOI |
8 | Scapoli L, Palmieri A, Lo Muzio L, Pezzetti F, Rubini C, Girardi A, Farinella F, Mazzotta M, Carinci F. MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol 2010;23:1229-34. DOI |
9 | Hromadnikova I, Kotlabova K, Jirasek JE, Doucha J. Detection of lacentaspecific microRNAs in maternal circulation. Ceska Gynekol 2010;75:252-6 [Czech]. |
10 | Su JL, Chen PB, Chen YH, Chen SC, Chang YW, Jan YH, Cheng X, Hsiao M, Hung MC. Downregulation of microRNA miR-520h by E1A contributes to anticancer activity. Cancer Res 2010;70:5096-108. DOI |
11 | Yu YH, Chen HA, Chen PS, Cheng YJ, Hsu WH, Chang YW, Chen YH, Jan Y, Hsiao M, Chang TY, et al. MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol. Oncogene 2013;32:431-43. DOI |
12 | Wang F, Xue X, Wei J, An Y, Yao J, Cai H, Wu J, Dai C, Qian Z, Xu Z, et al. hsamiR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations. Br J Cancer 2010;103:567-74. DOI |
13 | Cheng N, Brantley DM, Chen J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev 2002;13:75-85. DOI |
14 | Zhang J, Hughes S. Role of the ephrin and Eph receptor tyrosine kinase families in angiogenesis and development of the cardiovascular system. J Pathol 2006;208:453-61. DOI |
15 | Salvucci O, Tosato G. Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis. Adv Cancer Res 2012;114:21-57. |
16 | Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, Risau W, Klein R. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 1999;13:295-306. DOI |
17 | Steinle JJ, Meininger CJ, Forough R, Wu G, Wu MH, Granger HJ. Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway. J Biol Chem 2002;277:43830-5. DOI |
18 | Heroult M, Schaffner F, Augustin HG. Eph receptor and ephrin ligandmediated interactions during angiogenesis and tumor progression. Exp Cell Res 2006;312:642-50. DOI |
19 | Kuijper S, Turner CJ, Adams RH. Regulation of angiogenesis by Epheephrin interactions. Trends Cardiovasc Med 2007;17:145-51. DOI |
20 | Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T, Acker-Palmer A. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 2010;465:487-91. DOI |
21 | Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara A, Adams S, Davy A, Deutsch U, Luthi U, et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 2010;465:483-6. DOI |
22 | Horowitz A, Seerapu HR. Regulation of VEGF signaling by membrane traffic. Cell Signal 2012;24:1810-20. DOI |
23 | Yue PY, Wong DY, Ha WY, Fung MC, Mak NK, Yeung HW, Leung HW, Chan K, Liu L, Fan TP, et al. Elucidation of the mechanisms underlying the angiogenic effects of ginsenoside Rg(1) in vivo and in vitro. Angiogenesis 2005;8:205-16. DOI |
24 |
Chan LS, Yue P, Kok TW, Keung MH, Mak NK, Wong R. Ginsenoside-Rb1 promotes adipogenesis through regulation of |
25 | Kwok HH, Yue PYK, Mak NK, Wong RNS. Ginsenoside Rb1 induces type I collagen expression through peroxisome proliferator-activated receptordelta. Biochem Pharmacol 2012;84:532-9. DOI |
26 |
Kwok HH, Guo GL, Lau JKC, Cheng YK, Wang JR, Jiang ZH, Keung MH, Mak NK, Yue PY, Wong RN. Stereoisomers ginsenosides-20(S)- |
27 | Liu TG, Huang Y, Cui DD, Huang XB, Mao SH, Ji LL, Song HB, Yi C. Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice. BMC Cancer 2009;9:1471-2407. |
28 | Chen J, Peng H, Ou-Yang X, He X. Research on the antitumor effect of ginsenoside Rg3 in B16 melanoma cells. Melanoma Res 2008;18:322-9. DOI |
29 | Mochizuki M, Yoo YC, Matsuzawa K, Sato K, Saiki I, Tono-oka S, Samukawa K, Azuma I. Inhibitory effect of tumor metastasis in mice by saponins, ginsenoside-Rb2, 20(R)- and 20(S)-ginsenoside-Rg3, of red ginseng. Biol Pharm Bull 1995;18:1197-202. DOI |
30 | Yue PY, Wong DY, Wu PK, Leung PY, Mak NK, Yeung HW, Liu L, Cai Z, Jiang ZH, Fan TP, et al. The angiosuppressive effects of 20(R)-ginsenoside Rg3. Biochem Pharmacol 2006;72:437-45. DOI |
31 | Zhang Q, Kang X, Yang B, Wang J, Yang F. Antiangiogenic effect of capecitabine combined with ginsenoside Rg3 on breast cancer in mice. Cancer Biother Radiopharm 2008;23:647-53. DOI |
32 | Xu TM, Xin Y, Cui MH, Jiang X, Gu LP. Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis of ovarian cancer. Chin Med J (Engl) 2007;120:584-8. |
33 | Huang X, Hou M, Yi C, Song H. Anti-angiogenic effects of low-dose gemcitabine combined with ginsenoside Rg3 on mouse Lewis lung carcinoma. Zhongguo Fei Ai Za Zhi 2006;9:132-6 [Chinese]. |
34 | Kang XM, Zhang QY, Tong DD, Zhao W. Experimental study on antiangiogenesis in mice with Lewis lung carcinoma by low-dose of cyclophosphamide combined with ginsenoside Rg3. Zhongguo Zhong Xi Yi Jie He Za Zhi 2005;25:730-3 [Chinese]. |
35 | Chen MW, Ma AQ, Ni L, Huang C, Zhang DZ, Niu XY. Effect of ginsenoside on the cellular proliferation, apoptosis and cell cycles in LC A549 and HUVEC 304 cell lines. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2005;30:149-52 [Chinese]. |
36 | Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97. DOI |
![]() |